Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic

Jul 29, 2026. SAN FRANCISCO--(BUSINESS WIRE)--Adjuvia Therapeutics, a biotechnology company developing therapeutics to treat mitochondrial dysfunction and disease, today announced the closing of an $8 million Series Seed financing. The financing will support the submission of an Investigational New Drug (IND) application for Adjuvia's lead candidate, ATI-105, later this summer, followed by the initiation of the Phase 1 clinical trial in healthy volunteers in Fall 2026. Adjuvia also plans to begin a Phase 1/2 study in patients with Friedreich's ataxia in early 2027.

Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic